Citation

Karst A, Lister J. Ment. Health Clin. 2018; 8(5): 250-255.

Copyright

(Copyright © 2018, College of Psychiatric and Neurologic Pharmacists)

DOI

10.9740/mhc.2018.09.250

PMID

unavailable

Abstract

Clozapine remains the definitive gold standard for treatment-resistant schizophrenia despite limitations in use because of hematological abnormalities. Neutropenia or leukopenia are often treated with interruption of clozapine treatment, frequently resulting in clinical decompensation, hospitalization, increased burden to patient care, and increased risk of suicide. Colony-stimulating factors, including granulocyte colony-stimulating factors and granulocyte-macrophage colony-stimulating factors, are cytokines that stimulate proliferation and differentiation of myeloid precursor cells. Their use in the prevention and treatment of clozapine-associated neutropenia presents an alternative to clozapine discontinuation in certain cases. We present a case report of successful periodic granulocyte-macrophage colony-stimulating factor use with clozapine in a patient with treatment-resistant schizophrenia, as well as discussion of a practical approach to patients with possible clozapine-induced neutropenia or leukopenia. © 2018 CPNP.

Language: en

Keywords

Schizophrenia; Clozapine-induced blood dyscrasias; Clozapine-induced leukopenia; Clozapine-induced neutropenia; Granulocyte colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors